Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Soria

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Critical Care (London, England)|February 25, 2021
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreakAndrea Coppadoro, Annalisa Benini, Robert Fruscio, et al.
Journal of Hepatology|June 12, 2020
High rates of 30-day mortality in patients with cirrhosis and COVID-19Massimo Iavarone, Roberta D'Ambrosio, Alessandro Soria, et al.
Plos One|July 19, 2012
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experienceAmedeo Capetti, Simona Landonio, Paola Meraviglia, et al.
International Journal of Antimicrobial Agents|December 10, 2013
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E StudyAmedeo Capetti, Paola Meraviglia, Simona Landonio, et al.
Journal of Viral Hepatitis|December 11, 2020
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life settingMassimiliano Fabbiani, Andrea Lombardi, Marta Colaneri, et al.
Journal of Clinical Medicine|October 16, 2024
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-AdministrationValerio Rosato, Riccardo Nevola, Marcello Dallio, et al.
World Journal of Gastroenterology|January 2, 2026
Sex-based differences in hepatitis delta virus infection: Insights from the Italian PITER hepatitis delta virus cohortBarbara Coco, Maria Giovanna Quaranta, Maria Elena Tosti, et al.
Plos One|November 19, 2013
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trialStefano Rusconi, Paola Vitiello, Fulvio Adorni, et al.
Plos One|March 1, 2017
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, et al.
Plos One|January 3, 2018
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Critical Care (London, England)|February 25, 2021
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreakAndrea Coppadoro, Annalisa Benini, Robert Fruscio, et al.
Journal of Hepatology|June 12, 2020
High rates of 30-day mortality in patients with cirrhosis and COVID-19Massimo Iavarone, Roberta D'Ambrosio, Alessandro Soria, et al.
Plos One|July 19, 2012
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experienceAmedeo Capetti, Simona Landonio, Paola Meraviglia, et al.
International Journal of Antimicrobial Agents|December 10, 2013
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E StudyAmedeo Capetti, Paola Meraviglia, Simona Landonio, et al.
Journal of Viral Hepatitis|December 11, 2020
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life settingMassimiliano Fabbiani, Andrea Lombardi, Marta Colaneri, et al.
Journal of Clinical Medicine|October 16, 2024
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-AdministrationValerio Rosato, Riccardo Nevola, Marcello Dallio, et al.
World Journal of Gastroenterology|January 2, 2026
Sex-based differences in hepatitis delta virus infection: Insights from the Italian PITER hepatitis delta virus cohortBarbara Coco, Maria Giovanna Quaranta, Maria Elena Tosti, et al.
Plos One|November 19, 2013
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trialStefano Rusconi, Paola Vitiello, Fulvio Adorni, et al.
Plos One|March 1, 2017
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, et al.
Plos One|January 3, 2018
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, et al.
Pageof 6